Immunomodulating therapy of rheumatoid arthritis by high-dose intravenous immunoglobulin

Becker, H; Mitropoulou, Georgia; Helmke, K.

doi:10.1007/bf01892896

Cited by 15 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Case reports, open-label trials, and controlled studies of high-dose IVIG have shown some benefit in patients with rheumatoid arthritis (RA). [204][205][206][207][208][209] In contrast, low-dose (5 mg/kg every 3 weeks) therapy in a randomized, double-blind, placebo-controlled trial in 20 patients with refractory RA demonstrated no benefit. 210 Juvenile idiopathic arthritis.…”

Section: Rheumatic Diseasesmentioning

confidence: 99%

Update on the use of immunoglobulin in human disease: A review of evidence

Perez

Orange

Bonilla

et al. 2017

Journal of Allergy and Clinical Immunology

526

462

View full text Add to dashboard Cite

Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted.

show abstract

Section: Rheumatic Diseasesmentioning

confidence: 99%

Update on the use of immunoglobulin in human disease: A review of evidence

Perez

Orange

Bonilla

et al. 2017

Journal of Allergy and Clinical Immunology

526

462

View full text Add to dashboard Cite

show abstract

“…Non-specific immunoglobulins such as polyclonal IgG or IgM may also dissociate antigen-antibody complexes or inhibit their formation [8,[20][21][22]. In addition, large doses of non-immune IgG given intravenously may decrease the amount of circulating immune complexes [23,24], suppress auto-antibody production [25,26], and alter the proportions of T-cell populations [27] in some autoimmune diseases. These effects are commonly attributed to mechanisms mediated by specific antibodies which are assumed to be present in the preparations [25,28].…”

Section: Introductionmentioning

confidence: 99%

Modulation of Antigen‐Antibody Complexations by Immunoglobulins

et al. 1995

View full text Add to dashboard Cite

In this investigation, the modulating effects of non-immune human IgG and rheumatoid factors (RFs) on antigen-antibody complexations were studied. Non-immune human IgG, as well as RF, were found to inhibit the binding of antigen to specific antibodies of both human and rabbit origin. In addition, human immunoglobulins were also able to modify the composition of preformed antigen-antibody complexes. The effects were detected by immunological methods in two different antigen-antibody systems (human serum albumin-rabbit anti-HSA and tetanus toxoid-human anti-TT). Changes in biological activities could be followed by employing enzymes (glucose-6-phosphate dehydrogenase and human placental alkaline phosphatase) as antigens. The outcome of the effects was found to be dependent on the ratio of antigen to antibody, the antigen-binding properties of the antibody and its origin, and on the properties of the immunoglobulins added. The observed changes could not be explained only by the presence of specific antibodies in the immunoglobulin preparations. The ability of immunoglobulins to modulate antigen-antibody complexations may provide a rationale for the large amounts of non-specific immunoglobulins in the circulation by preventing premature precipitation and promoting the elimination of antigenic molecules.

show abstract

High‐dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis

Tumiati

Casoli

Veneziani

et al. 1992

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To investigate the efficacy of high‐dose intravenous immunoglobulin (IVIg) in the treatment of refractory rheumatoid arthritis (RA). Methods. Ten patients with active, severe RA that was unresponsive to first‐ and second‐line agents were administered IVIg monthly, for 6 months. Results. Following IVIg treatment, there was significant improvement in both subjective and objective parameters of disease activity in all 9 patients who completed the protocol. This improvement was noted to occur as early as after the second infusion of IVIg. After discontinuation of the treatment, all patients had a relapse of the disease within a few weeks. Conclusion. Since the reduction in clinical activity paralleled a decrease in the CD4+CDw29+: CD4+CD45RA+ cell ratio, some of the therapeutic benefits associated with IVIg may be due to a direct influence on the CD4+CD45RA+ subset. Although the possibility of carrying out further controlled studies on a larger scale is limited by the high cost of the treatment, IVIg appears to be an effective therapy for refractory RA.

show abstract

Immunomodulating therapy of rheumatoid arthritis by high-dose intravenous immunoglobulin

Cited by 15 publications

References 17 publications

Update on the use of immunoglobulin in human disease: A review of evidence

Update on the use of immunoglobulin in human disease: A review of evidence

Modulation of Antigen‐Antibody Complexations by Immunoglobulins

High‐dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis

Contact Info

Product

Resources

About